Background: Uveal melanoma (UVM) is the most common primary intraocular tumor in adults. However, identification of the effective biomarker for the diagnosis and treatment of UVM remains to be explored. Calcium and in...Background: Uveal melanoma (UVM) is the most common primary intraocular tumor in adults. However, identification of the effective biomarker for the diagnosis and treatment of UVM remains to be explored. Calcium and integrin-binding protein 1 (CIB1) is emerging as an important factor in tumor progression. Purpose: To determine the contribution of CIB1 in the diagnosis of UVM. Method: Immunohistochemical staining is used to detect the CIB1 expression level, while Gene Expression Profiling Interactive Analysis 2 (GEPIA2) and UALCAN online tools were used to analyze patient survival and CIB1 correlation genes in UVM. Integrative analysis using STRING and GeneMANIA predicted the correlated genes with CIB1 in UVM. Results: CIB1 expression level in UVM was significantly enhanced when compared with that in paracancerous tissues. A higher CIB1 expression level resulted in a significantly worse disease-free survival as well as overall survival. Moreover, the survival probability of patients was associated with body weight and gender of the patients with UVM. The correlated genes with CIB1 in UVM, and the similarity of the genes in UVM expression and survival heatmap were verified. Furthermore, Gene ontology enrichment analysis revealed that CIB1 and its correlated genes are significantly enriched in ITGA2B-ITGB3-CIB1 complex, regulation of intracellular protein transport and regulation of ion transport. Conclusions: Our novel findings suggested that CIB1 might be a potential diagnostic predictor for UVM, and might contribute to the potential strategy for UVM treatment by targeting CIB1.展开更多
Finding biomarkers for immunotherapy is an urgent issue in cancer treatment.Cellular retinoic acid-binding protein 2(CRABP2)is a controversial factor in the occurrence and development of human tumors.However,there is ...Finding biomarkers for immunotherapy is an urgent issue in cancer treatment.Cellular retinoic acid-binding protein 2(CRABP2)is a controversial factor in the occurrence and development of human tumors.However,there is limited research on the relationship between CRABP2 and immunotherapy response.This study found that negative correlations of CRABP2 and immune checkpoint markers(PD-1,PD-L1,and CTLA-4)were observed in breast invasive carcinoma(BRCA),skin cutaneous melanoma(SKCM),stomach adenocarcinoma(STAD)and testicular germ cell tumors(TGCT).In particular,in SKCM patients who were treated with PD-1 inhibitors,high levels of CRABP2 predicted poor prognosis.Additionally,CRABP2 expression was elevated in cancer-associated fibroblasts(CAFs)at the single-cell level.The expression of CRABP2 was positively correlated with markers of CAFs,such as MFAP5,PDPN,ITGA11,PDGFRα/βand THY1 in SKCM.To validate the tumor-promoting effect of CRABP2 in vivo,SKCM xenograft mice models with CRABP2 overexpression have been constructed.These models showed an increase in tumor weight and volume.Enrichment analysis indicated that CRABP2 may be involved in immunerelated pathways of SKCM,such as extracellular matrix(ECM)receptor interaction and epithelial-mesenchymal transition(EMT).The study suggests that CRABP2 may regulate immunotherapy in SKCM patients by influencing infiltration of CAFs.In conclusion,this study provides new insights into the role of CRABP2 in immunotherapy response.The findings suggest that CRABP2 may be a promising biomarker for PD-1 inhibitors in SKCM patients.Further research is needed to confirm these findings and to explore the clinical implications of CRABP2 in immunotherapy.展开更多
目的:探讨程序性死亡配体1(PD-L1)单克隆抗体是否可以增强ALDH high CSC-DC疫苗致敏的B细胞靶向ALDH high肿瘤干细胞(CSCs)的体液免疫作用。方法:建立B16-F10黑色素瘤小鼠模型,各组小鼠分别接受PBS、ALDH high CSC-DC+IgG、ALDH high CS...目的:探讨程序性死亡配体1(PD-L1)单克隆抗体是否可以增强ALDH high CSC-DC疫苗致敏的B细胞靶向ALDH high肿瘤干细胞(CSCs)的体液免疫作用。方法:建立B16-F10黑色素瘤小鼠模型,各组小鼠分别接受PBS、ALDH high CSC-DC+IgG、ALDH high CSC-DC疫苗、PD-L1单克隆抗体、ALDH high CSC-DC联合PD-L1单克隆抗体的治疗,记录小鼠的生存时间及肿瘤的体积。实验结束时收集各组小鼠的肿瘤,单个肿瘤细胞悬液进行ALDEFLUOR染色检测CSCs的比例。流式细胞术检测各组小鼠脾脏B细胞上PD-1的表达量。同时进一步行抗体结合试验和补体依赖的细胞毒性作用(CDC)试验检测B细胞培养上清中的抗体结合和裂解CSCs的能力。结果:相较于单独治疗组,PD-L1单克隆抗体与ALDH high CSC-DC疫苗的联合治疗可以更加显著地抑制肿瘤生长,延长小鼠生存时间。联合治疗组小鼠活化的B淋巴细胞上PD-1的表达水平显著降低,仅为6.5%。抗体结合试验提示,与ALDH high CSC-DC疫苗单独治疗组11.3%的结合率相比,联合治疗组小鼠B细胞培养上清中的抗体可以特异地结合15.7%ALDH high CSCs。同时CDC试验结果显示,联合治疗组的B细胞培养上清特异性地裂解ALDH high CSCs。结论:PD-L1单克隆抗体可以显著增强ALDH high CSC-DC疫苗致敏的B细胞产生靶向ALDH high CSCs的体液免疫反应。展开更多
文摘Background: Uveal melanoma (UVM) is the most common primary intraocular tumor in adults. However, identification of the effective biomarker for the diagnosis and treatment of UVM remains to be explored. Calcium and integrin-binding protein 1 (CIB1) is emerging as an important factor in tumor progression. Purpose: To determine the contribution of CIB1 in the diagnosis of UVM. Method: Immunohistochemical staining is used to detect the CIB1 expression level, while Gene Expression Profiling Interactive Analysis 2 (GEPIA2) and UALCAN online tools were used to analyze patient survival and CIB1 correlation genes in UVM. Integrative analysis using STRING and GeneMANIA predicted the correlated genes with CIB1 in UVM. Results: CIB1 expression level in UVM was significantly enhanced when compared with that in paracancerous tissues. A higher CIB1 expression level resulted in a significantly worse disease-free survival as well as overall survival. Moreover, the survival probability of patients was associated with body weight and gender of the patients with UVM. The correlated genes with CIB1 in UVM, and the similarity of the genes in UVM expression and survival heatmap were verified. Furthermore, Gene ontology enrichment analysis revealed that CIB1 and its correlated genes are significantly enriched in ITGA2B-ITGB3-CIB1 complex, regulation of intracellular protein transport and regulation of ion transport. Conclusions: Our novel findings suggested that CIB1 might be a potential diagnostic predictor for UVM, and might contribute to the potential strategy for UVM treatment by targeting CIB1.
基金supported by grants from the Natural Science Foundation of Hunan Province(2022JJ80044)the Youth Science Foundation of Xiangya Hospital(2019Q13).
文摘Finding biomarkers for immunotherapy is an urgent issue in cancer treatment.Cellular retinoic acid-binding protein 2(CRABP2)is a controversial factor in the occurrence and development of human tumors.However,there is limited research on the relationship between CRABP2 and immunotherapy response.This study found that negative correlations of CRABP2 and immune checkpoint markers(PD-1,PD-L1,and CTLA-4)were observed in breast invasive carcinoma(BRCA),skin cutaneous melanoma(SKCM),stomach adenocarcinoma(STAD)and testicular germ cell tumors(TGCT).In particular,in SKCM patients who were treated with PD-1 inhibitors,high levels of CRABP2 predicted poor prognosis.Additionally,CRABP2 expression was elevated in cancer-associated fibroblasts(CAFs)at the single-cell level.The expression of CRABP2 was positively correlated with markers of CAFs,such as MFAP5,PDPN,ITGA11,PDGFRα/βand THY1 in SKCM.To validate the tumor-promoting effect of CRABP2 in vivo,SKCM xenograft mice models with CRABP2 overexpression have been constructed.These models showed an increase in tumor weight and volume.Enrichment analysis indicated that CRABP2 may be involved in immunerelated pathways of SKCM,such as extracellular matrix(ECM)receptor interaction and epithelial-mesenchymal transition(EMT).The study suggests that CRABP2 may regulate immunotherapy in SKCM patients by influencing infiltration of CAFs.In conclusion,this study provides new insights into the role of CRABP2 in immunotherapy response.The findings suggest that CRABP2 may be a promising biomarker for PD-1 inhibitors in SKCM patients.Further research is needed to confirm these findings and to explore the clinical implications of CRABP2 in immunotherapy.
文摘目的:探讨程序性死亡配体1(PD-L1)单克隆抗体是否可以增强ALDH high CSC-DC疫苗致敏的B细胞靶向ALDH high肿瘤干细胞(CSCs)的体液免疫作用。方法:建立B16-F10黑色素瘤小鼠模型,各组小鼠分别接受PBS、ALDH high CSC-DC+IgG、ALDH high CSC-DC疫苗、PD-L1单克隆抗体、ALDH high CSC-DC联合PD-L1单克隆抗体的治疗,记录小鼠的生存时间及肿瘤的体积。实验结束时收集各组小鼠的肿瘤,单个肿瘤细胞悬液进行ALDEFLUOR染色检测CSCs的比例。流式细胞术检测各组小鼠脾脏B细胞上PD-1的表达量。同时进一步行抗体结合试验和补体依赖的细胞毒性作用(CDC)试验检测B细胞培养上清中的抗体结合和裂解CSCs的能力。结果:相较于单独治疗组,PD-L1单克隆抗体与ALDH high CSC-DC疫苗的联合治疗可以更加显著地抑制肿瘤生长,延长小鼠生存时间。联合治疗组小鼠活化的B淋巴细胞上PD-1的表达水平显著降低,仅为6.5%。抗体结合试验提示,与ALDH high CSC-DC疫苗单独治疗组11.3%的结合率相比,联合治疗组小鼠B细胞培养上清中的抗体可以特异地结合15.7%ALDH high CSCs。同时CDC试验结果显示,联合治疗组的B细胞培养上清特异性地裂解ALDH high CSCs。结论:PD-L1单克隆抗体可以显著增强ALDH high CSC-DC疫苗致敏的B细胞产生靶向ALDH high CSCs的体液免疫反应。